Braun Recalls Injectable Ceftazidime/Dextrose

Braun Medical has recalled one lot of ceftazidime for injection (2g) and dextrose for injection (50 ml) in its duplex container after stability test results were found to exceed the specification limits for high molecular weight polymers at the product’s 19 month stability interval. “Elevated levels of high molecular W

weight polymers have been shown to cause kidney damage and liver issues in animal studies,” a recall notice says. To date there have been no complaints or reports of adverse reactions associated with the product lot, it says. The cephalosporin antibacterial is indicated for treating the following infections caused by susceptible isolates of the designated microorganisms: Lower respiratory tract infections; skin and skin-structure infections; bacterial septicemia; bone and joint infections; gynecologic infections; intra-abdominal infections; and central nervous system infections.